AMBANI ORGANICS LT Overview
Ambani Orgochem is a four-decade-old, promoter-run Indian specialty-chemicals micro-cap. It is moving away from a commodity-adjacent base of water-based acrylic emulsions, binders, textile auxiliaries and metal-octoate paint driers. Its target is a "super-specialty" portfolio built on organic peroxides (polymerisation initiators and resin-curing agents) and salicylic acid with its salicylate esters (fragrance, UV-filter and pharmaceutical intermediates). Manufacturing sits at four units in MIDC Tarapur, Maharashtra, and a newer facility in Dahej, Gujarat. The Dahej plant was damaged by fire in February 2024 and restarted in February 2025. Revenue compounded at about 22–23% over five years, to ₹240.7 Cr in FY2026 and about ₹304 Cr on a trailing basis to September 2026. Profitability has lagged: EBITDA margins sit at 5–7% and net margins below 2%. The balance sheet is leveraged and working-capital heavy. The equity story now rests on Dahej ramp-up, product-mix upgrade, a capacity-led Tarapur expansion, and a pending ₹43.9 Cr preferential warrant raise.
Company's own description. In filings and press releases the company calls itself a manufacturer, processor, importer, supplier and exporter of water-based specialty chemicals. It names the paper, paint, textile, carpet and adhesive industries as customers. The FY2025 MD&A and the November 2025 press release extend the list to organic peroxides, salicylic acid and salicylic derivatives. They add pharmaceuticals, fragrances, cosmetics and home care as end markets. The company stresses "green chemistry": water-based, APEO-free and low-VOC formulations. It holds ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 certifications, plus GOTS and ZDHC certification for selected textile chemicals (FY2025 MD&A).
Independent characterisation. The company runs three economically distinct businesses under one reporting segment:
-
Legacy water-based polymers and auxiliaries (Tarapur). This covers acrylic and styrene-acrylic emulsions, PVA/PVP-type binders, thickeners, defoamers, dispersants, textile auxiliaries and detergent formulations. These are formulation-driven, moderately differentiated and price-competitive products. They sell to paint, paper, textile, carpet, construction and adhesive manufacturers. Raw-material pass-through (acrylic monomers, styrene, butyl acrylate) is high and margins are thin. The FY2026 investor presentation, as summarised by third parties, puts acrylic coatings and adhesives capacity at about 2,000 tonnes per month. It plans about 4,500 tonnes per month after a Tarapur expansion.
-
Metal carboxylates / paint driers and FRP accelerators (Tarapur, partly through subsidiary Om Maruti Glasswool & Wirenetting Products). Cobalt, manganese, lead, calcium, zinc, zirconium, iron, barium, cadmium, potassium and copper octoates and naphthenates, sold to paint, ink and FRP-composite makers.
-
Peroxide and salicylate platform (Dahej, plus earlier peroxide production from 2019). About 39 organic-peroxide grades sold under the "RAA PRO" brand, plus salicylic acid and 13 salicylate esters under the "AOPL" code. These are higher-value, hazard-intensive chemistries with fewer domestic producers. They serve polymer and composite makers, solar-encapsulant (EVA) producers, rubber vulcanisers, fragrance houses, personal-care formulators and pharma.
Business model and revenue model. Revenue is essentially 100% product sales of manufactured chemicals, with some traded material. There is no subscription, licensing or service revenue. Sales are B2B, made to order or from stock, through direct sales across about 20 Indian states and exports to over 40 countries (FY2026 investor presentation, per third-party summary). Exports are material. Foreign-exchange earnings were ₹76.44 Cr in FY2025, about 40% of revenue from operations (FY2025 Directors' Report).
Value-chain position. The company is a mid-stream converter. It buys petrochemical intermediates (acrylic monomers, styrene, tert-butanol/hydrogen peroxide derivatives, MEK, phenol/sodium phenolate for salicylic acid, metal salts, 2-ethylhexanoic acid) and sells functional ingredients that make up a small share of customers' bill of materials. It does not own feedstock. This leaves it exposed to raw-material volatility, mitigated only by price pass-through with a lag.
Customer types and end markets. Paint and coatings (decorative and industrial), paper, textiles and carpets, adhesives and construction chemicals, composite FRP (boats, wind-turbine blades, tanks, marble slabs, sanitaryware), polymers and LDPE, rubber and tyres, solar-panel EVA encapsulants, fragrance and flavour, personal care (sunscreens, anti-ageing creams), home care (detergents, air care), and pharmaceuticals (pain balms, acne preparations). No customer is named publicly. Customer concentration is not publicly disclosed. Infomerics describes the clientele as diversified (rating rationale, 30 Mar 2023).
Strategy
Stated strategy (themes from the FY2026 Annual Report Chairman's message, as excerpted, and the H1 FY2026 press release).
-
Becoming a "super-specialty" chemicals company. The FY2026 Annual Report states that strengthening its position as a super-specialty producer is a key priority, and that new molecules will strengthen its competitive position.
-
Mix upgrade toward value-added products. The November 2025 release cites a higher share of salicylates and peroxide derivatives as a revenue and margin driver. Management says it is exploring opportunities to supply more value-added products.
-
Dahej stabilisation and utilisation ramp. Production was improving month by month but still at partial capacity as of November 2025.
-
Capacity-led growth at Tarapur. Acrylic coatings and adhesives capacity is to rise from about 2,000 to about 4,500 t/month. Salicylic acid is to rise from about 50 to about 200 t/month (FY2026 investor presentation).
-
Operating efficiency. Working-capital efficiency, lower finance costs, supply-chain management and control of operating costs (November 2025 release).
-
Green chemistry positioning. Water-based, APEO-free, low-VOC products; ISO 14001, GOTS, ZDHC certifications.
Initiatives announced in the last 24 months (October 2024 – October 2026).
Medium-term targets and guidance. Management has given no numeric revenue, margin or capex guidance. Statements are qualitative ("more meaningful improvement in margins" in coming quarters, November 2025). No cost-programme targets or quantified sustainability commitments are disclosed.
Products & Services
Pricing models are not publicly disclosed for any product. All products are sold as bulk industrial chemicals on negotiated B2B pricing. Launch years are given where disclosed.
Organic Peroxides — "RAA PRO" range (production since 2019; Dahej scale-up 2023–2025)
| Product | Chemistry | Form | Active oxygen | Purity (%) | Principal applications |
|---|---|---|---|---|---|
| RAA PRO TB 70 / TB 75 / TB 80 | Tert-butyl hydroperoxide | Aqueous solution | 12.43% / 13.33% / 14.20% | 70 / 75 / 80 | Emulsion polymerisation, resins, agrochemicals, polyester curing, propylene oxide |
| RAA PRO DT 98 | Di-tert-butyl peroxide | Liquid | 10.70% | 98 | Emulsion polymerisation, specialty resins, fragrance, petrochemicals, LDPE |
| RAA PRO ME 6, ME 5 LWC, ME 5.5, ME V338, ME 6 PTFE, ME 4.5 LPT-IN, ME V395 | Methyl ethyl ketone peroxide (various carriers, incl. phthalate-free) | Solution | 8.5–10% | — | Unsaturated polyester (UP) resin curing: buttons, wind blades, boats, marble slabs, FRP tanks |
| RAA PRO PB 98 / PB 93 | Tert-butyl peroxybenzoate | Liquid / solution | 8.05% / 6.39–6.67% | 98 / 79.25 | UP curing, quartz marble, sanitaryware, grouts |
| RAA PRO TMH 98 | Tert-butyl peroxy-3,5,5-trimethylhexanoate | Liquid | 6.74% | 97 | UP curing, cure-in-place pipe |
| RAA PRO BP 75, BP 50 (several carriers incl. DMP, DCHP, DIBP, DBP, phthalate-free) | Dibenzoyl peroxide | Powder / paste | 3.27–4.95% | 50–75 | Auto putty, chemical anchors, UP curing, flour/sugar bleaching, APIs, acne creams |
| RAA PRO TBEC 985 / TBEC 975 | Tert-butyl peroxy-2-ethylhexyl carbonate | Liquid | 6.39% / 6.33% | 98.5 / 97.5 | Polymer production, solar-panel EVA encapsulant, crosslinking |
| RAA PRO CP 98 | Tert-butyl cumyl peroxide | Liquid | 7.22–7.37% | 95.5 | Rubber curing, EVA encapsulant, wire and cable |
| RAA PRO DTA | Di-tert-amyl peroxide | Liquid | 8.82% | 96 | High-solids varnishes, LDPE, acrylic polymerisation |
| RAA PRO TAEC / ECAC 6040 | Tert-amyl peroxy-2-ethylhexyl carbonate / TBEC-TAEC blend | Liquid | 5.89% / 6.15–6.20% | 96 / n/a | Solar EVA encapsulation, rubber vulcanisation, PVC |
| RAA PRO 279 / AAP | Acetylacetone peroxide (blend with TBPB / straight) | Liquid | 4.0–4.7% | n/a / 34.75 | Resin transfer moulding, vinyl ester, roof panels, FRP pipe |
| RAA PRO DCP 98 / DCP 99 | Dicumyl peroxide | Crystals | 5.79% / 5.85% | 98 / 99 | Rubber vulcanisation, shoe soles, tyres, EVA, thermoset composites |
| RAA PRO F 960 / F 40P / FMIX 3638 | Bis(tert-butylperoxyisopropyl)benzene | Powder / liquid | 3.4–9.07% | 96 / 40 / 37 | Polyolefin and rubber crosslinking, UP curing |
| RAA PRO CH 800 / CH 470 | Cumyl hydroperoxide | Liquid | 8.40% / 4.73–4.94% | 80 / 46 | Vinyl ester curing, phenol production, polymerisation catalyst |
| RAA PRO LP 98 / LP 99 | Dilauroyl peroxide | Powder / flakes | 3.93% / 3.97% | 98 / 99 | Polymerisation initiator, acrylics, thermosets |
| RAA PRO MIBK | Methyl isobutyl ketone peroxide | Liquid | 9.7–10.3% | — | RTM, vinyl ester, UP curing |
Source: company website product catalogue (accessed October 2026). Target customers: composite fabricators, polymer and LDPE producers, rubber compounders, solar-module encapsulant makers, pharma and food processors. Flagship view: the MEKP range (the volume curing agent for India's FRP industry) and the solar-EVA carbonates (TBEC/TAEC) are the most strategically relevant lines, given India's solar-module manufacturing build-out.
Salicylic Acid and Salicylates — "AOPL" range (salicylic acid plant commissioned 2023)
| Product | Chemistry | Purity | Applications |
|---|---|---|---|
| Salicylic acid | — | — | Pharma (aspirin, keratolytics), cosmetics, intermediates. Capacity planned to rise from about 50 to about 200 t/month (FY2026 presentation) |
| AOPL MS-99 | Methyl salicylate | 99–100.5% | Pain balms, gels, liniments, flavours |
| AOPL OS-99 | Octyl salicylate | ≥99% | UVB filter in sunscreens |
| AOPL BS-99 | Benzyl salicylate | ≥99% | Fragrance fixative, UV absorber |
| AOPL CS-96 | Cyclohexyl salicylate | ≥96% | Detergents, personal care, perfumes |
| AOPL 2EHS-99 | 2-Ethylhexyl salicylate | ≥99% | UVB filter, anti-ageing creams |
| AOPL AMS-99 | Amyl salicylate | ≥99% | Detergent and soap fragrance |
| AOPL BUS-98 | Butyl salicylate | ≥98% | Cosmetics, fine fragrance, household cleaners |
| AOPL HEPS-98 | Heptyl salicylate | ≥98% | Niche perfumery |
| AOPL HS-98 | Hexyl salicylate | ≥98% | Detergent, air-care, cosmetic fragrance |
| AOPL ALLS-98 | Allyl salicylate | ≥98% | Perfumes, air fresheners |
| AOPL IAMS-98 | Isoamyl salicylate | ≥98% | Soaps, aromatherapy |
| AOPL IBUS-98 | Isobutyl salicylate | ≥99% (as listed) | Candles, fabric softeners, detergents |
| AOPL PETS-98 | Phenyl ethyl salicylate | ≥98% | Candles, aromatherapy |
Source: company website (October 2026); FY2026 investor presentation (third-party summary). Target customers: fragrance and flavour houses, FMCG home and personal-care formulators, sunscreen makers, pharma.
Paint Driers and Metal Carboxylates — "AOPL" range (diversification from 2017)
| Product family | Metal-content grades (%) | Function |
|---|---|---|
| Cobalt octoate | 12, 10, 8, 6, 3 | Primary surface drier |
| Manganese octoate | 10, 8, 6 | Intermediate drier |
| Lead octoate | 36, 32, 24, 18 | Through drier (legacy chemistry) |
| Calcium octoate | 10, 6, 5, 3 | Auxiliary through drier, pigment wetting |
| Zinc octoate | 18, 12, 6 | Auxiliary drier, anti-wrinkle |
| Zirconium octoate | 24, 18, 12, 6 | Lead replacement, through drier |
| Copper naphthenate | 8.6, 8, 6 | Antifouling, wood and textile preservative |
| Iron octoate | 6, 4 | Stoving finishes |
| Barium octoate | 12 | Lead substitute |
| Cadmium octoate | 15.5, 15 | Heat stabiliser aid |
| Potassium octoate | 15 | Cobalt booster, UP curing, water-based coatings |
| Combination driers | AOPL 1025, 1028, 1068, 1425, 10725, 1121, 1123, 11 N9, 1345 (Co/Mn/Pb, Co/Pb/Ca, Co/Ca/Zr, Co/Ba) | Ready-to-use blends for enamels, inks, primers |
Source: company website. Target customers: decorative and industrial paint makers, printing-ink producers, FRP fabricators. The accelerators category on the website covers cobalt-type FRP accelerators; individual grades were not separately catalogued.
Water-based Emulsions, Binders and Textile/Process Chemicals (legacy core)
| Product line | Description | End market | Source |
|---|---|---|---|
| Acrylic emulsions | Pure acrylic and butyl-acrylate-based polymers | Paints, coatings, construction | IPO documents; website |
| Styrene-acrylic emulsions | Cost-optimised binders | Paints, paper coating | IPO documents |
| Butyl-acrylate-based terpolymers | Specialty binders | Coatings, textiles | IPO documents |
| PVP / PVA-type emulsions and binders | Binders and adhesives | Paper, adhesives, textiles | IPO documents; Infomerics |
| Adhesives | Water-based adhesive polymers | Packaging, wood, carpet | IPO documents; website |
| Thickeners | Rheology modifiers | Paints, textile printing | IPO documents |
| Defoamers and dispersants | Process aids | Paints, paper, textiles | IPO documents |
| Textile auxiliaries | Processing chemicals; some GOTS/ZDHC certified | Textile and carpet | FY2025 MD&A |
| Detergent formulations | Formulated cleaning chemicals | Industrial/household | IPO documents |
Capacity for acrylic coatings and adhesives is about 2,000 t/month, rising to about 4,500 t/month after the Tarapur expansion (FY2026 presentation, third-party summary). Specifications and grade names for this range were not published on the website at the time of review.
Financial Narrative
Basis: standalone unless stated. ₹ Cr. Sources: Infomerics rating releases (FY2022–FY2025 audited figures), FY2025 Directors' Report and MD&A, FY2026 audited-results filing (21 May 2026), FY2026 investor presentation (third-party summary), Screener.in (filing-derived, rounded to whole crores where marked). Blank cells mean not publicly disclosed. Consolidated and standalone figures differ by less than ₹0.1 Cr in most lines, because the subsidiaries are immaterial.
Income Statement
Notes: FY2022–FY2025 revenue and EBITDA are from Infomerics releases (30 Mar 2023, 24 Apr 2024, 11 Jul 2025). FY2026 revenue and gross profit are from aggregator mirrors of the audited filing. The ₹24,365.02 lakh figure some outlets call "revenue" is total income. FY2026 EBITDA is company-reported on a consolidated basis; the company's FY2024 and FY2025 EBITDA on the same basis were ₹5.11 Cr and ₹10.80 Cr, against Infomerics' ₹4.53 Cr and ₹9.31 Cr. FY2022–FY2023 PBT, depreciation and interest are Screener whole-crore roundings. Company-reported EPS is lower than the Screener basis because the company deducts 12% preference dividends (₹68.28 lakh paid in FY2025) from profit attributable to equity holders. Revenue CAGR: FY2021–FY2026 (5-year) 22.5%, from ₹87.36 Cr in FY2021 (Infomerics). FY2022–FY2026 (4-year) 17.6%.
Commentary. Revenue has scaled consistently. Two step-ups stand out: FY2022 (+44%, post-COVID restocking and price inflation in acrylic monomers) and FY2025 (+41%, Tarapur volume growth plus export momentum, despite Dahej being offline for most of the year). FY2023–FY2024 was a plateau, as the company diverted capital to Dahej (CWIP rose to ₹47 Cr in FY2023) while legacy volumes stagnated. Margins tell the opposite story. EBITDA margin compressed from 7.4% (FY2021) to 3.3% (FY2024) as the Dahej build-out absorbed overheads, raw-material costs stayed elevated, and the February 2024 fire cut contribution from the higher-margin peroxide line. Recovery since FY2025 (4.8%), FY2026 (6.8%) and H1 FY2027 (6.6%) coincides with Dahej's restart and a richer salicylate/peroxide mix, per management's November 2025 commentary. Bottom-line quality is poor. FY2024 profit of ₹3.0 Cr was flattered by a tax credit and about ₹5 Cr of other income. FY2025 swung to a loss because a ₹1.29 Cr deferred-tax reversal more than absorbed a thin ₹0.36 Cr PBT, itself supported by a ₹2.62 Cr exceptional item linked to the Dahej insurance settlement. FY2026 is the first year in three where operating profit, not one-offs, drove the result. Interest costs (₹8.4 Cr) still consumed over half of EBITDA.
Half-Yearly Trend (consolidated)
Sources: Company press release 18 Nov 2025 (H1 FY2025, H1 FY2026, ₹ lakh converted); MarketsMojo and Screener (H2 FY2026, H1 FY2027; whole-crore roundings for H2 FY2025). H1 FY2027 revenue grew 56.9% YoY. Net profit rose from ₹0.19 Cr to ₹3.45 Cr. Trailing-twelve-month revenue to September 2026 is ₹304.3 Cr; TTM net profit is about ₹4.6 Cr; TTM EPS is ₹5.46 (Screener).
Balance Sheet
Sources: Screener.in (filing-derived; whole crores). Infomerics PRs. FY2025 Auditor's Report (inventory, cited as ₹41.37 Cr in one table and ₹41.27 Cr in another). Cash for FY2025 is "cash flow / balance of ₹10.93 Cr as on 31 Mar 2025" per Infomerics. Short-term versus long-term debt split for FY2026 is not publicly disclosed. As of the July 2025 rating, rated facilities comprised ₹33.18 Cr of term loans and GECL, ₹27.50 Cr of fund-based working capital (cash credit plus usance bill discounting), and ₹40.18 Cr of non-fund-based and proposed short-term lines. Goodwill: none disclosed. Net worth at 30 Sep 2026 rose to about ₹63 Cr after warrant conversions; borrowings were ₹78 Cr (Screener).
Net debt. Net debt is about ₹49 Cr for FY2025 (₹59.63 Cr debt less ₹10.93 Cr cash). For other years it cannot be computed because cash is not publicly disclosed.
Working capital. Gross current-asset days were 233 (FY2021), 206 (FY2022), about 185 (FY2023), about 284 (FY2024) and about 232 (FY2025), per Infomerics. Large creditor balances, including letters of credit, finance the cycle. Payable days of 176–213 explain a negative cash-conversion cycle despite high inventory.
Cash Flow
Source: Screener.in. FY2025 investing cash flow was positive because the ₹20.49 Cr insurance receipt (26 Mar 2025) offset Dahej reconstruction capex. Screener's free-cash-flow series is computed on gross capex, including insurance-funded rebuild, and has been negative for five consecutive years. Cumulative FY2022–FY2026 FCF is about –₹66 Cr. It was funded by debt (borrowings up about ₹23 Cr) and equity from promoter infusion and warrants (Infomerics notes ₹18.45 Cr infused by promoters over FY2024–FY2025).
Ratios
Sources and method: ROE and ROA computed by the analyst from Screener net worth and total assets and filing net profit. ROCE, days ratios and CCC from Screener. Current ratio, gearing and interest coverage from Infomerics (FY2022–FY2025). FY2026 interest coverage is analyst-computed (16.37 / 8.41). ROIC is not computed separately because the tax line is too distorted for a reliable NOPAT; Screener ROCE serves as the proxy. Definitional conflict: the company's FY2025 MD&A reports debt-equity of 2.66x and interest coverage of 0.97x, on definitions that include other liabilities and different profit measures, against 1.25x and 1.20x per Infomerics. Net debt / EBITDA: about 5.2x in FY2025 (₹48.7 Cr / ₹9.31 Cr); not computable for other years.
Trend synthesis. Returns on capital are structurally sub-par. A 10-year average ROE of about 4% (Screener) sits well below any reasonable cost of equity. The FY2026 ROCE recovery to 11% is the best since FY2020 and is the key inflection to monitor. Leverage peaked in FY2023–FY2024, during the Dahej build and fire. It improved via equity injections, then edged up again in FY2026 as borrowings rose ₹16 Cr. The heavy use of supplier credit and LCs (payable days of 176–213) is both a funding strength and a fragility, since any tightening of LC lines would strain liquidity quickly.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Activity | FY2025 revenue | FY2025 net profit | Source |
|---|---|---|---|---|---|
Ambani Orgochem Limited | Listed parent | Manufacturing (Tarapur and Dahej) | ₹19,253.87 lakh (revenue from operations) | ₹(92.08) lakh | FY2025 Directors' Report |
Om Maruti Glasswool & Wirenetting Products Pvt Ltd | Subsidiary | Metal soaps (paint driers, FRP hardeners), per website | ₹6.01 lakh | ₹3.47 lakh | FY2025 Directors' Report (AOC-1) |
Omega Woven Mills Pvt Ltd | Subsidiary | Neighbouring unit (land/facility) | ₹6.00 lakh | ₹3.18 lakh | FY2025 Directors' Report (AOC-1) |
Results by Segment and Segment Margins & Growth (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Specialty chemicals revenue (INR Cr) | 136.20 | 192.54 | 240.74 |
YoY growth (%) | 2.6 | 41.4 | 25.0 |
Share of total revenue (%) | 100 | 100 | 100 |
Segment EBITDA (INR Cr) | 4.53 | 9.31 | 16.37 |
Segment EBITDA margin (%) | 3.33 | 4.84 | 6.80 |
Segment pre-tax income (INR Cr) | 0.20 | 0.36 | 4.10 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 126.04 | 132.78 | 136.20 | 192.54 | 240.74 |
Total income incl. other income (INR Cr) | — | — | 136.68 | 193.93 | 243.65 |
Revenue growth YoY (%) | 44.3 | 5.3 | 2.6 | 41.4 | 25.0 |
Gross profit (INR Cr) | — | — | — | — | 67.14 |
EBITDA (INR Cr) | 7.30 | 8.58 | 4.53 | 9.31 | 16.37 |
Depreciation and amortisation (INR Cr) | 1 | 1 | 2.79 | 3.04 | 4 |
Finance costs (INR Cr) | 3 | 4 | 7 | 7.78 | 8.41 |
Exceptional items (INR Cr) | 0 | 0 | 0 | 2.62 | — |
Profit before tax (INR Cr) | 3 | 3 | 0.20 | 0.36 | 4.1 |
Net profit (INR Cr) | 1.97 | 1.91 | 3.00 | -0.92 | 1.36 |
Net profit consolidated (INR Cr) | — | — | 3.04 | -0.85 | 1.33 |
EPS basic, Screener basis (INR) | 3.06 | 2.97 | 4.25 | -1.20 | 1.78 |
EPS basic, company-reported (INR) | — | — | — | -2.21 | 1.08 |
Dividend per equity share (INR) | 0 | 0 | 0 | 0 | 0 |
Gross margin (%) | — | — | — | — | 27.9 |
EBITDA margin (%) | 5.79 | 6.46 | 3.33 | 4.84 | 6.80 |
PBT margin (%) | 2.4 | 2.3 | 0.1 | 0.2 | 1.7 |
Net margin (%) | 1.56 | 1.44 | 2.20 | -0.48 | 0.56 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Half-Yearly)
| Metric | H1 FY2025 | H2 FY2025 | H1 FY2026 | H2 FY2026 | H1 FY2027 |
|---|---|---|---|---|---|
Revenue (INR Cr) | 81.75 | 112 | 109.15 | 133.09 | 171.22 |
EBITDA excl. other income (INR Cr) | 4.48 | 6 | 7.92 | 8.45 | 11.31 |
EBITDA margin (%) | 5.46 | 5.4 | 7.16 | 6.42 | 6.65 |
Finance costs (INR Cr) | 4 | 3 | 5 | 3.86 | 5.28 |
Net profit (INR Cr) | -1.78 | 1 | 0.19 | 1.14 | 3.45 |
EPS (₹, Screener) | -2.52 | 1.21 | 0.25 | 1.49 | 3.99 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 112 | 137 | 176 | 208 | 223 |
Net fixed assets incl. CWIP (INR Cr) | 29 | 66 | 64 | 81 | 86 |
Capital work in progress (INR Cr) | 9 | 47 | 8 | 7 | 11 |
Cash and equivalents (INR Cr) | — | 5.85 | — | 10.93 | — |
Total borrowings, Screener (INR Cr) | 53 | 52 | 61 | 60 | 76 |
Total debt, Infomerics (INR Cr) | 52.81 | 72.38 | 60.76 | 59.63 | — |
Equity share capital (INR Cr) | 6 | 6 | 7 | 8 | 8 |
Reserves (INR Cr) | 24 | 26 | 39 | 44 | 44 |
Net worth (INR Cr) | 30 | 32 | 46 | 52 | 52 |
Tangible net worth, Infomerics (INR Cr) | 30.83 | 32.07 | 45.19 | 51.18 | — |
Inventory (INR Cr) | — | — | — | 41.37 | — |
Other liabilities incl. trade payables (INR Cr) | 29 | 54 | 68 | 97 | 95 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | -7 | 23 | -12 | 12 | 0 |
Investing cash flow (INR Cr) | -11 | -38 | -1 | 2 | -8 |
Financing cash flow (INR Cr) | 26 | 11 | 14 | -3 | 8 |
Net change in cash (INR Cr) | 7 | -5 | 1 | 10 | -1 |
Free cash flow, Screener (INR Cr) | -19 | -16 | -13 | -9 | -9 |
Equity dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Preference dividends paid (INR Cr) | — | — | — | 0.68 | — |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
CFO / EBITDA (%) | -108 | 282 | -267 | 125 | 1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, net profit / avg net worth (%) | 8.0 | 6.2 | 7.7 | -1.9 | 2.6 |
ROA, net profit / avg total assets (%) | 2.1 | 1.5 | 1.9 | -0.5 | 0.6 |
ROCE, Screener (%) | 9 | 9 | 2 | 7 | 11 |
Current ratio (x) | 1.29 | 1.01 | 1.15 | 1.01 | — |
Debt / equity, Screener borrowings / net worth (x) | 1.77 | 1.63 | 1.33 | 1.15 | 1.46 |
Gearing, Infomerics (x) | 1.71 | 2.26 | 1.43 | 1.25 | — |
Gross debt / EBITDA (x) | 7.3 | 6.1 | 13.5 | 6.4 | 4.6 |
Interest coverage, EBITDA / interest (x) | 2.15 | 2.29 | 0.67 | 1.20 | 1.95 |
Asset turnover, revenue / avg assets (x) | 1.33 | 1.07 | 0.87 | 1.00 | 1.12 |
Debtor days | 93 | 77 | 71 | 80 | 76 |
Inventory days | 75 | 77 | 100 | 103 | 89 |
Payable days | 63 | 142 | 194 | 213 | 176 |
Cash conversion cycle (days) | 105 | 12 | -22 | -30 | -11 |
Region Overview
| Region | FY2025 |
|---|---|
Export revenue, FX earnings proxy (INR Cr) | 76.44 |
Domestic revenue, derived (INR Cr) | 116.10 |
Export share of revenue (%) | 39.7 |
FX outgo (INR Cr) | 0.26 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | ₹175.10 (19 Oct 2026); ₹169.75–170 (16 Oct 2026) | ScanX; MarketsMojo; Screener |
52-week range | ₹94.90 – ₹175.10 | ScanX; Screener |
IPO price / listing price | ₹66 / ₹66.65 (18 Jul 2018) | IPO Central |
Return since IPO | About +165% at ₹175 (about 11.9% CAGR over 8.25 years) | Analyst calculation |
Price CAGR (Screener) | 1-year 21%; 3-year 10%; 5-year 11% | Screener (16 Oct 2026) |
5-year price return (MarketsMojo) | +61.67% | MarketsMojo |
Market capitalisation | ₹147–156 Cr | Screener; ScanX; analyst |
Valuation Multiples
| Multiple | Ambani Orgochem | Basis | Source |
|---|---|---|---|
P/E (TTM) | About 32x at ₹175 (TTM EPS ₹5.46). Aggregators show 37.7x (Screener, ₹170) and 108–110x (MarketsMojo / ScanX, on FY2026 EPS) | TTM versus FY2026 | Screener; ScanX; analyst |
P/B | About 2.4x (₹175 / book value ₹72.9); 2.56–2.76x per aggregators | Sep 2026 book | Screener; MarketsMojo |
EV/EBITDA | About 11.6x TTM (analyst: about ₹229 Cr EV on gross debt / ₹19.8 Cr TTM EBITDA); 12.5x per MarketsMojo | TTM | Analyst; MarketsMojo |
EV/Sales | About 0.75x TTM; 0.83x per MarketsMojo | TTM | Analyst; MarketsMojo |
Industry P/E | About 42x | Sector | MarketsMojo |
Peer P/E | Fine Organic 38.2x; Atul 22.5x; Aarti Industries 34.4x; Pidilite 57.1x | Trailing | eduinvesting peer table |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per equity share (INR) | 0 | 0 | 0 | 0 | 0 |
Promoter holding at year end (%) | 63.59 | 63.59 | 57.95 | 61.25 | 61.25 |
Number of shareholders at year end | — | 210 | 251 | 281 | 280 |
Capital Programmes
| Programme | Size | Price | Outcome | Source |
|---|---|---|---|---|
FY2024 warrants | 41.26 lakh | ₹80 | 12.26 lakh converted (listed Nov 2023 – Jan 2024 and Nov 2024); 29.00 lakh forfeited (₹5.80 Cr to general reserve) | FY2025 Directors' Report; NSE circulars |
FY2025 warrants | 12.60 lakh | ₹90 | Allotted 27 Feb 2025; fully converted by 19 Aug 2026 (₹11.34 Cr gross) | NSE filing, 19 Aug 2026 |
FY2027 warrants (proposed) | 43.925 lakh | ₹100 (implied) | EGM 26 Oct 2026 | NSE filings, 16 Oct 2026 |
Analyst Conclusions
Management guidance. Qualitative only. Management expects continued margin improvement, Dahej utilisation gains, a mix shift to salicylates and peroxides, and capacity additions at Tarapur. No numerical targets.
Consensus expectations. None; no coverage.
Run-rate reference (not guidance). H1 FY2027 annualised revenue is about ₹340 Cr. EBITDA margin is about 6.6%. Interest is about ₹10.6 Cr annualised.
Bull case.
-
Operating leverage from Dahej. H1 FY2027 revenue (+57%) and net profit (₹3.45 Cr against ₹0.19 Cr) show the post-fire restart flowing to the bottom line. Each 100 bp of EBITDA margin on about ₹340 Cr of revenue adds about ₹3.4 Cr, roughly equal to H1 FY2027 net profit.
-
Equity-funded deleveraging and capacity. The ₹43.9 Cr warrant raise could retire over half of ₹76 Cr of borrowings or fund the 4x salicylic and 2.25x acrylic expansions. Either path would lift interest coverage from about 2x toward 4x and lower the cost of capital.
-
Structural niches. Solar-EVA crosslinkers, phthalate-free curing agents and salicylate UV filters align with fast-growing Indian demand pools. Licensed hazardous-chemistry capacity is a genuine barrier.
Bear case.
-
Chronic low returns. A 10-year average ROE of about 4%, five years of negative FCF, and margins far below specialty peers (6.8% versus about 18% at Fineotex) suggest a commodity business wearing specialty labels.
-
Dilution and governance. The warrants could add about 49% to the share count at ₹100, about 43% below the current price. The SME exemption, recurrent filing inconsistencies and serial warrant programmes (one largely forfeited) temper governance comfort.
-
Execution and safety concentration. One fire cost a year of Dahej output. Phase 2 slipped twice. The valuation re-rating (P/B of about 2.4x; a 32% move in five days) prices in execution that has not yet been demonstrated on a full-year basis.
Catalysts and monitorables (next 12 months).
-
26 Oct 2026 EGM: approval, allottee list (promoter participation?), and stated use of proceeds.
-
H2 FY2027 results (around May 2027): can EBITDA margin hold at or above 6.5% and net margin exceed 1.5% for a full year?
-
Commissioning evidence for Dahej Phase 2 and the Tarapur acrylic expansion.
-
Settlement of the Dahej loss-of-profit insurance claim.
-
Next Infomerics review (due around July 2026–2027): upgrade potential if leverage falls.
-
Working-capital trend, especially payable days, and any LC-line changes.
-
Disclosure quality: segment, export and capacity data in the next annual report.
Concluding analyst verdict. Ambani Orgochem is at an operational inflection, but not yet a financial one. Four facts anchor the bull narrative. Revenue has doubled in three years, from ₹136 Cr in FY2024 to a ₹304 Cr trailing run-rate. The Dahej peroxide and salicylate platform is back online after the February 2024 fire. EBITDA margin has recovered from 3.3% to about 6.6%. H1 FY2027 delivered the best half-year profit in the company's history. Management's strategic direction toward organic peroxides and salicylates is sound. These chemistries carry real barriers to entry and fit Indian demand themes in composites, solar, fragrance and personal care.
The quality of earnings, however, still lags the narrative. Interest absorbs about half of EBITDA. Free cash flow has been negative for five years. Ten-year average ROE of about 4% has never covered the cost of capital. Disclosure is thin, with no segment, product, customer or R&D data. Capacity figures are inconsistent across company sources. Governance is promoter-dominated under SME exemptions, and equity has been raised repeatedly through warrants. The proposed 43.9 lakh warrants at about ₹100 would materially dilute holders. They would, though, also repair the balance sheet. Whether they are value-accretive depends on undisclosed objects and allottees.
At about ₹175, the stock trades on roughly 32x trailing earnings, 2.4x book and about 11–12x EV/EBITDA. That is not demanding for a company growing revenue above 30%, provided margins keep expanding. It is expensive for a business whose sustainable net margin remains unproven above 1.5%. Our assessment is a speculative, execution-dependent turnaround. The investment case strengthens materially if three conditions hold: full-year FY2027 EBITDA margin above 7%, warrant proceeds directed to deleveraging or high-return capacity, and Dahej running incident-free at high utilisation. Absent these, the recent re-rating looks premature. Liquidity, at 280 shareholders and thin SME trading, adds a further discount.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | In role since | Age | Background | Source |
|---|---|---|---|---|---|
Rakesh Hasmukhlal Shah | Promoter, Managing Director | Board since 7 Mar 1996 | 56 | Over three decades in the chemical industry; leads the company since 1996 | MarketScreener; Infomerics; company website |
Apooni Rakesh Shah | Promoter, Whole-time Director (listed as Chairperson by MarketScreener) | 1 Apr 2018 | 57 | Co-promoter; signatory on exchange filings (DIN 00503116) | MarketScreener; NSE filings |
Paresh Harsuklal Shah | Chief Executive Officer | 1 Apr 2018 | — | Holds 1,100 shares (promoter group) | MarketScreener; Trendlyne |
Bhavesh Babulal Pandya | Chief Financial Officer | 1 Apr 2018 | — | — | MarketScreener; FY2025 Directors' Report |
Vaanie Dangi | Company Secretary and Compliance Officer | 11 Sep 2023 | — | — | MarketScreener; FY2025 Directors' Report |
Dinesh More | Chief Administrative Officer | 24 Aug 2013 | — | — | MarketScreener |
“—” = not publicly disclosed.
Board of Directors
| Name | Category | Appointed | Age | Source |
|---|---|---|---|---|
Apooni Rakesh Shah | Executive (Whole-time Director), promoter | 1 Apr 2018 | 57 | MarketScreener |
Rakesh Hasmukhlal Shah | Executive (Managing Director), promoter | 7 Mar 1996 | 56 | MarketScreener |
Prakash Anna Mahanwar | — | 1 Apr 2018 | 58 | MarketScreener |
Bhavin Jitendra Patel | Non-executive (additional director Feb 2024; regularised 30 Apr 2024) | 19/20 Feb 2024 | 30 | MarketScreener; Directors' Report |
Neerajkumar Amarjeet Pandey | Non-executive; retired by rotation at the 39th AGM and sought reappointment | 19/20 Feb 2024 | 54 | MarketScreener; Directors' Report |
Rajesh Vasudeo Desai | — | 3 Dec 2025 | 68 | MarketScreener |
Mahesh Shrirang Jagdale | — | 23 Jul 2026 | — | MarketScreener |
“—” = not publicly disclosed.
Directors' Remuneration
| Person | FY2026 total compensation | Source |
|---|---|---|
"CEO" (Simply Wall St designation; likely the Managing Director) | ₹1.3 million (about ₹13 lakh) | Simply Wall St, 18 Oct 2026 |
Shareholding Trend
| Holder category | Mar 2021 | Sep 2022 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
Promoter and promoter group (%) | 72.67 | 63.59 | 57.95 | 61.25 | 61.25 | 54.30 | 52.59 |
Public (%) | 27.33 | 36.41 | 42.05 | 38.75 | 38.75 | 45.70 | 47.41 |
Number of shareholders | — | 212 | 251 | 281 | 280 | 284 | 280 |
Major Shareholders
| Holder | Stake | As of | Source |
|---|---|---|---|
Rakesh Hasmukhlal Shah (promoter) | 48.94% (43,64,721 shares) | Aug 2026 | MarketsMojo; promoter disclosure Jul 2026 |
Apooni Rakesh Shah (promoter) | About 3.5% (3,14,738 shares; 4.11% pre-dilution) | Nov 2024 share count | Trendlyne |
MNS Securities Limited (public) | 7.85% (7,00,000 shares) | 19 Aug 2026 | NSE filing |
Chintan Vidyut Shah (public) | 1.07% (95,000 shares) | 19 Aug 2026 | NSE filing |
Jyotindra Ramniklal Doshi (promoter group) | About 0.11% (10,000 shares) | Nov 2024 share count | Trendlyne |
Paresh H. Shah (promoter group / CEO) | About 0.01% (1,100 shares) | Nov 2024 share count | Trendlyne |
Bodies corporate (aggregate) | 13.55% (10 holders) | Nov 2024 | Trendlyne |
Competitive Landscape
Peer Comparison
| Platform | Competitors | Type | Relative positioning |
|---|---|---|---|
Organic peroxides | Nouryon (India operations; reported India peroxide expansion), Arkema, United Initiators, NOF Corporation, Pergan, Chinese producers (Jiangsu Yuanyang, Zibo Zhenghua) | Global majors and Chinese exporters | Ambani is a small domestic challenger competing on local supply, short lead times and price for MEKP, BPO and solar-EVA grades |
Salicylic acid and salicylates | Novacyl (Seqens), Alta Laboratories (India), Chinese salicylic-acid producers; aroma-chemical producers such as Oriental Aromatics and Privi Speciality Chemicals for esters | Global and Indian | Small-capacity entrant (about 50 t/month); import-substitution play |
Acrylic emulsions, binders, adhesives | Pidilite Industries, Nikhil Adhesives, BASF India, Dow, Synthomer, Jubilant Agri & Consumer Products | Indian majors and multinationals | Price-taker in a fragmented market; niche in paper, textile and carpet binders |
Textile auxiliaries | Fineotex Chemical, Archroma, Huntsman, Sarex | Indian and multinational | Small, GOTS/ZDHC-certified niche supplier |
Paint driers / metal carboxylates | Borchers (Milliken), Umicore, regional Indian producers | Global and unorganised domestic | Broad grade range incl. lead-free systems; limited scale |
Peer Comparison FY2026
| Company | Revenue FY2026 | YoY growth (%) | EBITDA margin (%) | Net profit | Net margin (%) | R&D intensity |
|---|---|---|---|---|---|---|
Ambani Orgochem | 240.74 | 25.0 | 6.8 | 1.36 | 0.6 | Not disclosed (nil reported FY2025) |
Fineotex Chemical | 772.2 | 44.8 | 17.7 | 108.8 | 14.1 | — |
Fine Organic Industries | 2,482.5 | 4.9 | — | 417 | 16.8 | — |
Pidilite Industries | 14,867 | 11.1 | — | 2,471 | 16.6 | — |
“—” = not publicly disclosed.



